Karmetadin of the tab. of p/o of 35 mg No. 60

tablets Karmetadin are shown to adults for symptomatic treatment of stable stenocardia at insufficient efficiency or intolerance of anti-anginal medicaments of the first line.

Structure

Active ingredient: trimetazidina digadrokhlorid;

1 tablet supports a trimetazidin of dihydrochloride of 35 mg;

Excipients: calcium hydrophosphate anhydrous, silicon dioxide colloidal anhydrous, polyethylene oxide, povidone, xanthane gum, magnesium stearate;

Film cover: Opadry® II Brown 85G565010 (polyvinyl alcohol, talc, polyethyleneglycol, titan dioxide (E 171), lecithin (soy) ferrous oxide red (E 172)); magnesium stearate, glycerin.

Contraindication

• Hypersensitivity to active ingredient or to any excipient.
• Parkinson's disease, parkinsonism symptoms, a tremor, a syndrome of "uneasy legs" and other motive disorders concerning above-mentioned.
• Heavy renal failure (clearance of creatinine <30 ml/min.).

Route of administration

One tablet of 35 mg of a trimetazidin two times a day at meal time.

Drug is used inside in the morning and in the evening.

After 3 months of treatment needs to estimate treatment outcome and in the absence of effect trimetazidin it is necessary to cancel.

Use is not recommended to

Feature of use

.

Drivers

With care.

Amount of data on overdose trimetazidiny is limited to

. Symptomatic treatment.

Side effects

• from digestive tract: pain in abdominal area of a stomach, diarrhea, dyspepsia, nausea and vomiting.
• from skin and hypodermic fabric: rash, itching, urticaria.
• General disturbances: asthenia.

Interaction

Interaction with other medicines. In particular, trimetazidin it is possible to appoint in a combination with heparin, kaltsipariny, antagonists of vitamin K, peroral lipidosnizhayushchy drugs, aspirin, β-blockers, antagonists of calcium, foxglove medicaments (trimetazidin does not influence digoxin level in blood plasma).

to Store

at a temperature not above 25 °C out of children's reach.

Expiration date - 3 years.